EMAIL THIS PAGE TO A FRIEND

The Journal of surgical research

Resolvin D1 attenuates lipopolysaccharide induced acute lung injury through CXCL-12/CXCR4 pathway.


PMID 24387839

Abstract

The recruitment of neutrophils plays an important role in the progress of acute lung injury (ALI). Excessive neutrophils released from bone marrow accumulate in lung, release proinflammatory factors, and cause tissue damage. CXCL-12/CXCR4 is an important signaling pathway, which regulates the migration of bone marrow hematopoietic cells out of bone marrow and involves in neutrophil accumulation and retention in the inflammatory site. Resolvin D1 (RvD1) is a kind of lipid mediators, which can alleviate many inflammatory diseases. We hypothesized that RvD1 can alleviate lipopolysaccharide (LPS)-induced ALI through regulating CXCL-12/CXCR4 pathway. We randomized mice into five groups: control group, RvD1 group, LPS group, LPS plus RvD1 group, and LPS plus AMD3100 group. ALI was established by intratracheal instillation of LPS. After 24 and 72 h, mice were sacrificed, and lung tissues were harvested for histologic analysis, wet-to-dry ratio, myeloperoxidase activity, and CXCL-12 expression. Bronchoalveolar fluid was collected for protein analysis, cytokines assay, and flow cytometry analysis. Histologic findings as well as wet-to-dry ratio, protein concentration, cytokines assay, neutrophil number, and myeloperoxidase activity confirmed that RvD1 and AMD3100 alleviated LPS-induced ALI. RvD1 decreased CXCL-12 messenger RNA expression in lung. However, RvD1 promoted CXCR4 expression in neutrophils in the initial stage of inflammation and reduced its level in the later stage. RvD1 protects LPS-induced ALI partially through regulating CXCL-12/CXCR4 pathway.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

53171
cis-4,7,10,13,16,19-Docosahexaenoic acid, analytical standard
C22H32O2
D2534
cis-4,7,10,13,16,19-Docosahexaenoic acid, ≥98%
C22H32O2
L2005 Lactoperoxidase from bovine milk, lyophilized powder (essentially salt-free), ≥200 units/mg protein
61328 Lactoperoxidase from bovine milk, lyophilized, powder, ≥150 U/mg
M6908 Myeloperoxidase from human leukocytes, lyophilized powder, ≥50 units/mg protein
68528 Peroxidase from Bjerkandera adusta, ≥2.8 U/mg
P8375 Peroxidase from horseradish, Type VI, essentially salt-free, lyophilized powder, ≥250 units/mg solid (using pyrogallol)
77332 Peroxidase from horseradish, lyophilized, powder, beige, ~150 U/mg
P6782 Peroxidase from horseradish, Type VI-A, essentially salt-free, lyophilized powder, ≥250 units/mg solid (using pyrogallol), 950-2000 units/mg solid (using ABTS)
P8250 Peroxidase from horseradish, Type II, essentially salt-free, lyophilized powder, 150-250 units/mg solid (using pyrogallol)
P8125 Peroxidase from horseradish, Type I, essentially salt-free, lyophilized powder, 50-150 units/mg solid (using pyrogallol)
P8415 Peroxidase from horseradish, Type XII, essentially salt-free, lyophilized powder, ≥250 units/mg solid (using pyrogallol)
P6140 Peroxidase from horseradish, Type X, ammonium sulfate suspension
P2088 Peroxidase from horseradish, Highly stabilized, essentially salt-free, lyophilized powder, 200-300 units/mg solid (using pyrogallol)